McKesson (MCK)
(Delayed Data from NYSE)
$595.73 USD
+5.74 (0.97%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $595.76 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$595.73 USD
+5.74 (0.97%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $595.76 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
If You Invested $1000 in McKesson 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Surging Earnings Estimates Signal Upside for McKesson (MCK) Stock
by Zacks Equity Research
McKesson (MCK) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Are These Medical Stocks a Great Value Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Ideas feature highlights: Henry Schein, AmerisourceBergen and McKesson
by Zacks Equity Research
Henry Schein, AmerisourceBergen and McKesson are included in this Investment Ideas blog.
The Stock-Picking Puzzle: Putting The Pieces Together
by Bryan Hayes
The Stock-Picking Puzzle: Putting The Pieces Together
Company News for Feb 4, 2022
by Zacks Equity Research
Companies In The News Are: TMUS, MCK, ALL, AFL.
McKesson (MCK) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter 2022 results benefit from considerable growth across all segments.
McKesson (MCK) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 14.31% and 3.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Feb 2: BSX, TMO & More
by Riya Anand
Medical Products companies' Q4 results are likely to reflect an increase in COVID-19 testing demand. Let's see how BSX, TMO, HOLX and MCK are poised ahead of their earnings releases.
McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Is a Surprise Coming for McKesson (MCK) This Earnings Season?
by Zacks Equity Research
McKesson (MCK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
McKesson (MCK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
McKesson (MCK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed at $246.97 in the latest trading session, marking a +0.55% move from the prior day.
McKesson (MCK) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is Why Growth Investors Should Buy McKesson (MCK) Now
by Zacks Equity Research
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Should Value Investors Buy These Medical Stocks?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Will McKesson (MCK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Add Omnicell (OMCL) Stock for Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) on strength in medication management and adherence automation solutions.
3 Reasons Growth Investors Will Love McKesson (MCK)
by Zacks Equity Research
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why You Should Hold on to NextGen (NXGN) Stock Now
by Zacks Equity Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. Intense competition is a headwind.
Here's Why You Should Hold on to Globus Medical (GMED) for Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED), backed by strength in the Enabling Technologies arm and ExcelsiusGPS platforms.
3 Reasons to Add McKesson (MCK) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about McKesson (MCK) owing to its robust Biologics business.
Walgreens (WBA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Faster adoption of digital health and recent partnerships are expected to have contributed to Walgreens' (WBA) first-quarter performance.
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
by Zacks Equity Research
Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.
Envista (NVST) Gets FDA 510 (k) Approval for N1 Implant System
by Zacks Equity Research
Envista (NVST) noted that the Nobel Biocare N1 system represents a significant step further in patient-centric dental implant solutions.